liu.seSearch for publications in DiVA
Change search
Link to record
Permanent link

Direct link
BETA
Starkhammar, Hans
Publications (10 of 24) Show all publications
Drott, J., Fomichov, V., Starkhammar, H., Börjeson, S., Kjellgren, K. I. & Berterö, C. (2019). Oxaliplatin-Induced Neurotoxic Side Effects and Their Impact on Daily Activities. Cancer Nursing, 42(6), E40-E48
Open this publication in new window or tab >>Oxaliplatin-Induced Neurotoxic Side Effects and Their Impact on Daily Activities
Show others...
2019 (English)In: Cancer Nursing, ISSN 0162-220X, E-ISSN 1538-9804, Vol. 42, no 6, p. E40-E48Article in journal (Refereed) Published
Abstract [en]

Background: Oxaliplatin (OXA) is frequently used in the treatment of patients with colorectal cancer, and OXA-induced neurotoxic side effects are common. Reports on real-time patient-reported neurotoxic side effects and impact on the patient's daily activities are sparse in existing studies. Objective: The aim of this study was to identify and assess patient-reported OXA-induced neurotoxic side effects and their impact on the patient's daily activities, during and after chemotherapy. Methods: In a multicenter prospective longitudinal study, 46 chemo-naïve patients with colorectal cancer treated with postoperative adjuvant OXA-based chemotherapy were monitored during treatment and at 3-, 6-, 9-, and 12-month follow-ups. Patients were recruited from September 2013 to June 2016. In total, 370 Oxaliplatin-Associated Neurotoxicity Questionnaire responses were available for analysis. A mobile phone-based system was used to receive real-time assessments. Results: All patients reported neurotoxic side effects and impact on daily activities during treatment. The side effects changed in character and body location over time and had an impact on the daily activities. Conclusions: The high prevalence of OXA-induced neurotoxic side effects significantly interfered with the patients' daily activities. We found significant differences between baseline data and follow-up time points for neurotoxicity, and the patients had not returned to baseline after 1 year. Implications for Practice: The real-time assessment using mobile phone technology seems to be a valuable tool for monitoring patient-reported neurotoxicity and interventions for tailored care. Effectively identifying neurotoxicity and its impact on the patient's daily activities is important in supportive cancer care.

Place, publisher, year, edition, pages
Lippincott Williams & Wilkins, 2019
Keywords
Cancer nursing; Chemotherapy; Colorectal cancer; Daily activities, mHealth; Neurotoxicity; Patient-reported outcomes; Symptom control
National Category
Nursing
Identifiers
urn:nbn:se:liu:diva-154883 (URN)10.1097/ncc.0000000000000674 (DOI)000494795400005 ()
Note

Funding agencies: Swedish Cancer SocietySwedish Cancer Society; Linkoping University

Available from: 2019-03-04 Created: 2019-03-04 Last updated: 2019-11-27
Drott, J., Starkhammar, H., Kjellgren, K. I. & Berterö, C. (2018). Neurotoxic Side Effects Early in the Oxaliplatin Treatment Period in Patients With Colorectal Cancer. Oncology Nursing Forum, 45(6), 690-697
Open this publication in new window or tab >>Neurotoxic Side Effects Early in the Oxaliplatin Treatment Period in Patients With Colorectal Cancer
2018 (English)In: Oncology Nursing Forum, ISSN 0190-535X, E-ISSN 1538-0688, Vol. 45, no 6, p. 690-697Article in journal (Refereed) Published
Abstract [en]

PURPOSE: To identify and describe experiences of patients with colorectal cancer (CRC) who have neurotoxic side effects early in the oxaliplatin treatment period, and how neurotoxicity affects their daily lives.

PARTICIPANTS & SETTING: 10 patients with stage II-III CRC were included. All were treated with adjuvant oxaliplatin postoperatively and assessed neurotoxicity via a platform-independent mobile phone-based system. Patients were recruited from two hospitals in southern Sweden from November 2013 to August 2014.

METHODOLOGIC APPROACH: Qualitative interview study conducted through open-ended, face-to-face, qualitative interviews. Thematic analysis was used.

FINDINGS: A main theme was identified.

IMPLICATIONS FOR NURSING: Nurses have an obligation to communicate the importance of early detection of neurotoxicity. Mobile phone technology seems to be a valuable tool for monitoring patient-reported neurotoxicity to improve communication and supportive care.

Place, publisher, year, edition, pages
Pittsburgh, PA, United States: Oncology Nursing Society, 2018
Keywords
chemotherapy, colorectal cancer, daily life, neurotoxicity, qualitative methodology
National Category
Cancer and Oncology Nursing
Identifiers
urn:nbn:se:liu:diva-154815 (URN)10.1188/18.ONF.690-697 (DOI)000459360700005 ()30339148 (PubMedID)2-s2.0-85055071697 (Scopus ID)
Note

Funding agencies: Swedish Cancer Society; Division of Nursing Science, Department of Medical and Health Sciences at Linkoping University

Available from: 2019-02-28 Created: 2019-02-28 Last updated: 2019-04-10Bibliographically approved
Drott, J., Starkhammar, H., Kjellgren, K. & Berterö, C. (2016). The trajectory of neurotoxic side effects' impact on daily life: a qualitative study. Supportive Care in Cancer, 24(8), 3455-3461
Open this publication in new window or tab >>The trajectory of neurotoxic side effects' impact on daily life: a qualitative study
2016 (English)In: Supportive Care in Cancer, ISSN 0941-4355, E-ISSN 1433-7339, Vol. 24, no 8, p. 3455-3461Article in journal (Refereed) Published
Abstract [en]

PURPOSE:

The purpose of this study was to explore the experiences of oxaliplatin-induced neurotoxic side effects among patients with colorectal cancer (CRC) and how these side effects influenced their daily lives over time.

METHODS:

To assess neurotoxic side effects, ten patients were repeatedly interviewed. The patients were recruited from two hospitals in south of Sweden, had stage II-III CRC, and had been treated with adjuvant oxaliplatin postoperatively, from November 2013 to October 2015. They had received FOLFOX and XELOX, with a mean total dose of 791 mg oxaliplatin. After completed chemotherapy, at 3, 6, and 12 months into the post-treatment phase, 25 interviews were conducted and thematic analysis was used according to Braun and Clarke.

RESULTS:

Oxaliplatin-induced neurotoxicity affects patients in several ways in the long term. Four themes were identified: Expectation of cure, Dubiety, Normalization, and Learn to live with neurotoxicity. The findings of this study describe the trajectory of neurotoxicity and its impact on these patients' life situation. The findings confirmed that neurotoxicity is multi-faceted and that the experience of it changes over time.

CONCLUSION:

The desire to survive stimulates adaptations and strategies to manage daily life, and patients learn to live with the neurotoxic side effects. This study provides evidence that these patients need individual attention and support during the trajectory of neurotoxic side effects. Current care provision is inadequate due to a lack of knowledge of the ways in which neurotoxicity impacts the patient's daily life. This study provides insights that could be used to develop a more person-centered care.

Keywords
Adjuvant chemotherapy; Colorectal cancer; Neurotoxicity; Oxaliplatin; Qualitative interviews; Thematic analysis
National Category
Nursing
Identifiers
urn:nbn:se:liu:diva-126626 (URN)10.1007/s00520-016-3179-1 (DOI)000378884400030 ()26992409 (PubMedID)
Note

Funding agencies:We thank all patients for their participation in this study. We also thank the Swedish Cancer Society, the Department of Oncology and Surgery, Linkoping University Hospital, and the Division of Nursing Science at the Department of Medical and Health Sciences for the financial support. Further thanks go to all the health professionals in the oncology clinics who were involved in the study in different ways.

Available from: 2016-03-31 Created: 2016-03-31 Last updated: 2018-05-15
Heedman, P. A., Canslatt, E., Henriks, G., Starkhammar, H., Fomichov, V. & Sjödahl, R. (2015). Variation at presentation among colon cancer patients with metastases: a population-based study. Colorectal Disease, 17(5), 403-408
Open this publication in new window or tab >>Variation at presentation among colon cancer patients with metastases: a population-based study
Show others...
2015 (English)In: Colorectal Disease, ISSN 1462-8910, E-ISSN 1463-1318, Vol. 17, no 5, p. 403-408Article in journal (Refereed) Published
Abstract [en]

AimThe study aimed to describe and follow a 2year cohort of colon cancer patients with Stage IV disease from presentation to long-term outcome. MethodThe records of 177 colon cancer patients diagnosed in southeast Sweden during 2009-2010 with disseminated disease at presentation were reviewed retrospectively. ResultsThe patients were heterogeneous with respect to age, performance status and survival. Despite metastatic disease, local symptoms from the primary tumour dominated the initial clinical picture. Forty-one per cent had anaemia. The time from suspicion of colon cancer to established diagnosis of disseminated disease varied from 0 to 231days (emergency cases included, median 12days). The majority (77%) were diagnosed in hospital. In 53% the primary tumour and the metastases were not diagnosed on the same occasion which may increase the risk for misinformation or delays in the care process. The possibility of simultaneous diagnosis was doubled when the patient was investigated as an inpatient. Patients were seen by one to 12 physicians (median three) in the investigation phase, and one to 47 (median 11) from diagnosis until the last record in the hospital notes. The 1-year survival was 46%. ConclusionPatients with metastatic colon cancer at presentation are heterogeneous and warrant an adapted multidisciplinary approach to achieve the goal of individualized treatment for each patient in accordance with the Swedish national cancer strategy.

Place, publisher, year, edition, pages
Wiley: 12 months, 2015
Keywords
Colon cancer; diagnostic approach; metastases; heterogeneity; decision making; integrated care
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-118033 (URN)10.1111/codi.12864 (DOI)000353565100014 ()25511984 (PubMedID)
Available from: 2015-05-21 Created: 2015-05-20 Last updated: 2019-02-11
Drott, J., Starkhammar, H., Börjeson, S. & Berterö, C. (2014). Identifying Oxaliplatin induced Neurotoxicity in Medical records - strengthening compassion. In: : . Paper presented at 18th ICCN (International Conference on Cancer Nursing), September 7-11, 2014, Panama City, Panama.
Open this publication in new window or tab >>Identifying Oxaliplatin induced Neurotoxicity in Medical records - strengthening compassion
2014 (English)Conference paper, Oral presentation only (Other academic)
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-110636 (URN)
Conference
18th ICCN (International Conference on Cancer Nursing), September 7-11, 2014, Panama City, Panama
Available from: 2014-09-17 Created: 2014-09-17 Last updated: 2016-09-26
Drott, J., Starkhammar, H., Börjeson, S. & Berterö, C. (2014). Oxaliplatin induced neurotoxicity among patients with colorectal cancer: documentation in medical records - a pilot study. Open Journal of Nursing, 4, 265-274
Open this publication in new window or tab >>Oxaliplatin induced neurotoxicity among patients with colorectal cancer: documentation in medical records - a pilot study
2014 (English)In: Open Journal of Nursing, ISSN 2162-5336, E-ISSN 2162-5344, Vol. 4, p. 265-274Article in journal (Refereed) Published
Abstract [en]

Patients with colorectal cancer (CRC) can have chemotherapy with oxaliplatin postoperatively.Oxaliplatin can cause acute and chronic neurotoxicity. It is important to be aware of neurotoxicside effects so they can be documented and action taken at an early stage. The study aimed toidentify and explore neurotoxic side effects documented in the medical records of patients withcolorectal cancer treated with oxaliplatin-based adjuvant chemotherapy. Data in this study weremedical records; presenting documentation about patients treated at the University Hospital inthe south of Sweden between 2009 and 2010. A summative content analysis approach was used toexplore the neurotoxic side effects. Identification and quantification of the content of medical recordswere carried out by using a study-specific protocol. “Cold sensitivity” and “tingling in thehands” were the most frequently documented neurotoxicity-related terms in the medical records.This identification was followed by interpretation. Three categories were identified in the interpretivepart of the study: acute, chronic, and degree of neurotoxicity. The results show the importanceof awareness of neurotoxic side effects so that they can be documented and action taken atan early stage. The documentation could be more reliable if patient-reported structured measurementswere used, combined with free descriptions in the medical records. Being able to followthe progression of the symptoms during and after treatment would improve patient’s safety andalso quality of life. The protocol that we developed and used in this review of medical records maybe helpful to structure the documentation in the electronic system for documentation of neurotoxicityside effects.

 

Place, publisher, year, edition, pages
Scientific Research Publishing, 2014
Keywords
Adjuvant Oxaliplatin Chemotherapy, Colorectal Cancer, Medical Record Review, Neurotoxicity
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-105867 (URN)10.4236/ojn.2014.44031 (DOI)
Available from: 2014-04-11 Created: 2014-04-11 Last updated: 2018-05-15Bibliographically approved
Sjödahl, R., Rosell, J. & Starkhammar, H. (2013). Causes of death after surgery for colon cancer-impact of other diseases, urgent admittance, and gender. Scandinavian Journal of Gastroenterology, 48(10), 1160-1165
Open this publication in new window or tab >>Causes of death after surgery for colon cancer-impact of other diseases, urgent admittance, and gender
2013 (English)In: Scandinavian Journal of Gastroenterology, ISSN 0036-5521, E-ISSN 1502-7708, Vol. 48, no 10, p. 1160-1165Article in journal (Refereed) Published
Abstract [en]

Objective. In patients with colon cancer, high age and comorbidity is common. In this population-based retrospective study we have investigated causes of death and the influence of urgent operation, and gender on survival. Material and methods. Medical records of 413 patients with verified colon cancer were reviewed. The diagnosis was made during 2000-2006 and operation was performed in 385 patients (93%). Results. The overall 5-year survival after surgery was 48.3%. At the end of the follow-up, 128 patients (54.9%) had verified colon cancer when they died but 105 patients (45.1%) had no signs of colon cancer. Their 5-year survival was 5.5% and 41.9%, respectively (p andlt; 0.0001). Median survival time was significantly shorter after urgent compared with elective admittance, 20.7 months versus 77.9 months, and the 5-year survival 32.4% versus 57.9% (p = 0.0001). The tumor stage at operation was more favorable in patients dying with no signs of colon cancer than in those dying with cancer regarding stage I-II (66.7% versus 16.4%), and stage IV (1.0% versus 53.1%), but not regarding stage III (30.5% versus 29.7%). The overall survival in women who were operated was longer than in men (p = 0.045) as well as survival after elective admittance (p = 0.013). Conclusion. After a median follow-up of 56.1 months almost half of the patients who were dead had died from other causes than colon cancer. Ten percent of those patients had an incorrectly reported diagnosis of colon cancer as cause of death. Urgent admittance was associated with reduced survival time. The median survival time was longer in women than in men.

Place, publisher, year, edition, pages
Informa Healthcare, 2013
Keywords
colon cancer, comorbidity, neoplasm, survival, urgent admittance
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-99407 (URN)10.3109/00365521.2013.828771 (DOI)000324761000008 ()
Available from: 2013-10-17 Created: 2013-10-17 Last updated: 2017-12-06
Börjeson, S., Starkhammar, H., Unosson, M. & Berterö, C. (2012). Common Symptoms and Distress Experienced Among Patients with Colorectal Cancer: A Qualitative part of Mixed Method Design. Open Nursing Journal, 6(1), 100-107
Open this publication in new window or tab >>Common Symptoms and Distress Experienced Among Patients with Colorectal Cancer: A Qualitative part of Mixed Method Design
2012 (English)In: Open Nursing Journal, ISSN 1874-4346, E-ISSN 1874-4346, Vol. 6, no 1, p. 100-107Article in journal (Refereed) Published
Abstract [en]

Background :

Colorectal cancer is one of the most common types of tumour in the world. Treatment side effects, together with the tumour symptoms, can result in a ‘symptom burden’. To understand the patient’s burden during chemotherapy treatment and plan effective symptom relief there is a need for more knowledge about the experience of symptoms from the patients’ perspective.

Objectives :

The study was designed to qualitatively identify and describe the most common symptoms among patients treated for colorectal cancer, and discover whether there are barriers to reporting symptoms.

Methods :

Thirteen Swedish patients diagnosed with colorectal cancer and treated with chemotherapy were interviewed face-to-face. The interviews were audio-taped and transcribed verbatim. The transcripts were analysed by following the principles of qualitative content analysis.

Results :

Nine symptoms/forms of distress were identified. Those most frequently expressed were fatigue, changed bowel habits, and affected mental well-being, closely followed by nausea, loss of appetite and neurological problems. Of particular note were the affected mental well-being, the magnitude of the neurological problems described, the symptoms related to skin and mucous membrane problems, and the reports of distressing pain. Barriers to symptom control were only expressed by the patients in passing and very vaguely.

Conclusion :

This study confirms other reports on most common symptoms in colorectal cancer. It also highlights the early onset of symptoms and provides data on less well-studied issues that warrant further study, namely affected mental well-being, the magnitude of the neurological problems and symptoms related to the skin and mucous membranes. Nurses need to be sensitive to the patients’ need presented and not only noting symptoms/distresses they have guidelines for.

Place, publisher, year, edition, pages
Bentham Open, 2012
Keywords
Colorectal cancer, distress, qualitative content analysis, symptoms
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-87145 (URN)10.2174/1874434601206010100 (DOI)
Available from: 2013-01-10 Created: 2013-01-10 Last updated: 2017-12-06
Drott, J., Berterö, C., Börjeson, S. & Starkhammar, H. (2012). Neurotoxiska symtom vid adjuvant cytostatikabehandling hos patienter med kolorektalcancer. Paper presented at Kirurgveckan i Linköping 2012,20-24 augusti.
Open this publication in new window or tab >>Neurotoxiska symtom vid adjuvant cytostatikabehandling hos patienter med kolorektalcancer
2012 (Swedish)Conference paper, Poster (with or without abstract) (Other academic)
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-90997 (URN)
Conference
Kirurgveckan i Linköping 2012,20-24 augusti
Available from: 2013-04-11 Created: 2013-04-11 Last updated: 2016-09-26
Tveit, K. M., Guren, T., Pfeiffer, P., Sorbye, H., Pyrhonen, S., Sigurdsson, F., . . . Christoffersen, T. (2012). Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study. Journal of Clinical Oncology, 30(15), 1755-1762
Open this publication in new window or tab >>Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study
Show others...
2012 (English)In: Journal of Clinical Oncology, ISSN 0732-183X, E-ISSN 1527-7755, Vol. 30, no 15, p. 1755-1762Article in journal (Refereed) Published
Abstract [en]

Purpose less thanbrgreater than less thanbrgreater thanThe NORDIC-VII multicenter phase III trial investigated the efficacy of cetuximab when added to bolus fluorouracil/folinic acid and oxaliplatin (Nordic FLOX), administered continuously or intermittently, in previously untreated metastatic colorectal cancer (mCRC). The influence of KRAS mutation status on treatment outcome was also investigated. less thanbrgreater than less thanbrgreater thanPatients and Methods less thanbrgreater than less thanbrgreater thanPatients were randomly assigned to receive either standard Nordic FLOX (arm A), cetuximab and FLOX (arm B), or cetuximab combined with intermittent FLOX (arm C). Primary end point was progression-free survival (PFS). Overall survival (OS), response rate, R0 resection rate, and safety were secondary end points. less thanbrgreater than less thanbrgreater thanResults less thanbrgreater than less thanbrgreater thanOf the 571 patients randomly assigned, 566 were evaluable in intention-to-treat (ITT) analyses. KRAS and BRAF mutation analyses were obtained in 498 (88%) and 457 patients (81%), respectively. KRAS mutations were present in 39% of the tumors; 12% of tumors had BRAF mutations. The presence of BRAF mutations was a strong negative prognostic factor. In the ITT population, median PFS was 7.9, 8.3, and 7.3 months for the three arms, respectively (not significantly different). OS was almost identical for the three groups (20.4, 19.7, 20.3 months, respectively), and confirmed response rates were 41%, 49%, and 47%, respectively. In patients with KRAS wild-type tumors, cetuximab did not provide any additional benefit compared with FLOX alone. In patients with KRAS mutations, no significant difference was detected, although a trend toward improved PFS was observed in arm B. The regimens were well tolerated. less thanbrgreater than less thanbrgreater thanConclusion less thanbrgreater than less thanbrgreater thanCetuximab did not add significant benefit to the Nordic FLOX regimen in first-line treatment of mCRC.

Place, publisher, year, edition, pages
American Society of Clinical Oncology: JCO, 2012
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-78817 (URN)10.1200/JCO.2011.38.0915 (DOI)000304427600008 ()
Note
Funding Agencies|Kjell Magne Tveit||Merck Serono||sanofi-aventis||Bengt Glimelius||Eli Lilly||Per Pfeiffer||Roche||Halfdan Sorbye||Seppo Pyrhonen||Anders Johnsson||Fridbjorn Sigurdsson||Merck Serono (Darmstadt, Germany)||sanofi-aventis (Oslo, Norway)||Norwegian Cancer Society||Swedish Cancer Society (Cancerfonden)||Available from: 2012-06-21 Created: 2012-06-21 Last updated: 2017-12-07
Organisations

Search in DiVA

Show all publications